Coegin Pharma

3.70 SEK

+2.21 %

Less than 1K followers

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+2.21 %

-14.55 %

-16.67 %

-33.93 %

+26.28 %

-11.06 %

-68.99 %

-90.66 %

-88.37 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Market cap

105.79M SEK

Turnover

303.17K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26.2

2026

Annual report '25

21.5

2026

Interim report Q1'26

21.5

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release21 hours ago

Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position

Press release1/2/2026, 8:30 AM

Coegin Pharma provides an operational and strategic update

Press release12/22/2025, 12:30 PM

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release12/19/2025, 8:25 AM

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Press release12/12/2025, 10:50 AM

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Regulatory press release11/27/2025, 8:45 AM

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Regulatory press release11/20/2025, 1:50 PM

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Press release11/14/2025, 1:42 PM

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Press release11/6/2025, 1:45 PM

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Regulatory press release10/17/2025, 3:05 PM

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Press release10/13/2025, 8:02 AM

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Regulatory press release9/17/2025, 12:30 PM

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Regulatory press release9/10/2025, 1:00 PM

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Regulatory press release8/21/2025, 12:30 PM

Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025

Press release8/20/2025, 6:30 AM

Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product

Regulatory press release8/12/2025, 12:45 PM

Coegin Pharma changes language for company communication to English

Press release7/2/2025, 6:30 AM

Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide

Regulatory press release5/22/2025, 11:30 AM

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Regulatory press release5/22/2025, 6:35 AM

Coegin Pharma AB publishes its quarterly report for the first quarter of 2025

Regulatory press release4/29/2025, 10:45 AM

Coegin Pharma AB publishes Annual Report for the financial year 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.